Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q13277
UPID:
STX3_HUMAN
Alternative names:
-
Alternative UPACC:
Q13277; B4DME0; O43750; O43751; Q15360
Background:
Syntaxin-3 plays a crucial role in the nervous system and gastrointestinal tract, facilitating synaptic vesicle docking and membrane fusion of apical vesicles. It is essential for the survival of retinal photoreceptors and acts as a regulator of gene expression.
Therapeutic significance:
Linked to Retinal dystrophy and microvillus inclusion disease, and Diarrhea 12 with microvillus atrophy, understanding Syntaxin-3's role could unveil new therapeutic strategies for these severe conditions.